ANIX — Anixa Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Anixa Biosciences Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Anixa and Moffitt Complete Fourth CAR-T Dosing in Ovarian Cancer Trial; Patients Exceed Survival Benchmarks
Brief: Anixa Biosciences Announces Treatment Of Second Patient In Fourth Cohort Of Ovarian Cancer Car-T Clinical Trial
Brief: Dr. Wenham to speak on ovarian cancer immunotherapy at Ovarcoming Conference
Brief: Anixa Begins FDA-Approved IND Transfer for Phase 2 Breast Cancer Vaccine Trial
Brief: Anixa Biosciences Receives Notice Of Allowance From Canadian Intellectual Property Office For Patent Covering Breast Cancer Vaccine Technology
Brief: Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Brief: Anixa Biosciences Announces Poster Presentation On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025
Brief: Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine
Brief: Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent
Brief: Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office
Brief: Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Brief: Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Brief: Anixa Biosciences Board Of Directors Approves Purchase Of Bitcoin As Treasury Reserve Asset
Brief: Anixa Biosciences Initiates Dosing In Third Cohort In Its Ovarian Cancer Car-T Clinical Trial
Brief: Anixa Biosciences Announces Timing Of Public Release Of Data From The Phase 1 Study Of Its Breast Cancer Vaccine
Brief: Anixa Biosciences Announces Second Dose Administered To Patient In Ovarian Cancer Clinical Trial
Brief: Anixa Biosciences Submits Protocol Amendment For Car-T Trial
Brief: Anixa Biosciences Unveils Phase 2 Study Plan For Breast Cancer Vaccine